Shopping Cart

No products in the cart.

Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Nutritional strategies for improving sarcopenia outcomes in older adults: A narrative review.

Sarcopenia is characterized by a decline in muscle strength, generalized loss of skeletal muscle mass, and impaired physical performance, which are common outcomes used to screen, diagnose, and determine severity of sarcopenia in older adults. These outcomes are associated with...
๐Ÿ—“๏ธ 2024-10-01
๐Ÿ“ฐ Publication: Pharmacology Research & Perspectives
Read MoreNutritional strategies for improving sarcopenia outcomes in older adults: A narrative review.

Mitochondrial pathways and sarcopenia in the geroscience era.

Sarcopenia is associated with structural, ultrastructural, and molecular abnormalities of skeletal muscle. Mitochondrial dysfunction is a pivotal factor involved in muscle aging and sarcopenia. Mitochondrial bioenergetics are significantly reduced in muscles of older adults which is associated with whole-body aerobic...
๐Ÿ—“๏ธ 2024-10-19
๐Ÿ“ฐ Publication: Journal Of Nutrition Health & Aging
Read MoreMitochondrial pathways and sarcopenia in the geroscience era.

Impact of sarcopenia and muscle strength on postoperative complication risk following pancreatic resection.

The association between sarcopenia and postoperative complications has been widely reported in patients with cancer. Yet, the lack of standardized population-specific diagnostic cut-off points and assessments of muscle strength is hampering prospective clinical utilization. Therefore, we aimed to examine the...
๐Ÿ—“๏ธ 2024-10-11
Read MoreImpact of sarcopenia and muscle strength on postoperative complication risk following pancreatic resection.

Frailty or sarcopenia: which is a better indicator of mortality risk in older adults?

Despite the different conditions, frailty and sarcopenia overlap regarding their common link: the assessment of walking speed and muscle strength. This study aimed to compare the frailty phenotype to the sarcopenia using different cut-off points for low grip strength to...
๐Ÿ—“๏ธ 2024-10-11
๐Ÿ“ฐ Publication: Journal Of Epidemiology And Community Health
Read MoreFrailty or sarcopenia: which is a better indicator of mortality risk in older adults?

Myofiber-specific FoxP1 knockout protects against pancreatic cancer-induced muscle wasting in male but not female mice.

Cancer cachexia affects up to 80% of cancer patients and results in reduced quality of life and survival. We previously demonstrated that the transcriptional repressor Forkhead box P1 (FoxP1) is upregulated in skeletal muscle of cachectic mice and people with...
๐Ÿ—“๏ธ 2024-09-21
Read MoreMyofiber-specific FoxP1 knockout protects against pancreatic cancer-induced muscle wasting in male but not female mice.

Sarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy.

The impact of computed tomography-defined sarcopenia on outcomes in head and neck cancer has been well described. Sarcopenic obesity (SO) (depleted muscle mass combined with obesity) may pose a more serious risk than either condition alone. We investigated SO and...
๐Ÿ—“๏ธ 2024-09-30
๐Ÿ“ฐ Publication: British Journal Of Nutrition
Read MoreSarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy.

LRRK2 Gene Mutation Causes Skeletal Muscle Impairment in Animal Model of Parkinson's Disease.

While the gradually aggravated motor and non-motor disorders of Parkinson's disease (PD) lead to progressive disability and frequent falling, skeletal muscle impairment may contribute to this condition. The leucine-rich repeat kinase2 (LRRK2) is a common disease-causing gene in PD. Little...
๐Ÿ—“๏ธ 2024-09-23
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLRRK2 Gene Mutation Causes Skeletal Muscle Impairment in Animal Model of Parkinson's Disease.

The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

With limited treatment options, cachexia remains a major challenge for patients with cancer. Characterizing the interplay between tumor cells and the immune microenvironment may help identify potential therapeutic targets for cancer cachexia. Herein, we investigate the critical role of macrophages...
๐Ÿ—“๏ธ 2024-03-29
๐Ÿ“ฐ Publication: Cancer Cell
Read MoreThe crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

Finding sensitive clinical outcome measures has become crucial in natural history studies and therapeutic trials of neuromuscular disorders. Here, we focus on 1-year longitudinal data from quantitative magnetic resonance imaging (MRI) and phosphorus magnetic resonance spectroscopy (P MRS) in a...
๐Ÿ—“๏ธ 2024-04-13
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

The BET inhibitor JQ1 targets fat metabolism and counteracts obesity.

Obesity, one of the most frequent health problems in the adult population, is a condition characterized by excessive white adipose tissue accumulation and accompanied by the increased risk to develop other disorders such as type II diabetes, cardiovascular disorders, physical...
๐Ÿ—“๏ธ 2024-02-15
๐Ÿ“ฐ Publication: Journal Of Advanced Research
Read MoreThe BET inhibitor JQ1 targets fat metabolism and counteracts obesity.

Mitochondrial Quantity and Quality in Age-Related Sarcopenia.

Sarcopenia, the age-associated decline in skeletal muscle mass and strength, is a condition with a complex pathophysiology. Among the factors underlying the development of sarcopenia are the progressive demise of motor neurons, the transition from fast to slow myosin isoform...
๐Ÿ—“๏ธ 2024-02-08
๐Ÿ“ฐ Publication: International Journal Of Molecular Sciences
Read MoreMitochondrial Quantity and Quality in Age-Related Sarcopenia.

Cancer cachexia: biomarkers and the influence of age.

Cancer cachexia (Ccx) is a complex metabolic condition characterized by pronounced muscle and fat wasting, systemic inflammation, weakness and fatigue. Up to 30% of cancer patients succumb directly to Ccx, yet therapies that effectively address this perturbed metabolic state are...
๐Ÿ—“๏ธ 2024-02-27
๐Ÿ“ฐ Publication: Molecular Oncology
Read MoreCancer cachexia: biomarkers and the influence of age.

Cancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

This comprehensive review sheds light on cancer cachexia (CC), a significant condition marked by muscle wasting in cancer patients, emphasizing its molecular mechanisms and potential treatments. Highlighting the challenge CC presents, especially in older individuals, the article discusses the multifaceted approach needed to combat this syndrome.
๐Ÿ—“๏ธ January 2024
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreCancer Cachexia: Molecular Mechanisms and Therapeutic Strategies
Age-Related Spinal Deformity: a Consequence of Sarcopenia?

Age-Related Spinal Deformity: a Consequence of Sarcopenia?

This study investigates the connection between sarcopenia and age-related spinal deformities, focusing on lumbar paravertebral muscles (PVM) quality and volume. Results show that sarcopenic patients have higher ectopic fat infiltration in PVM, contributing to spinal deformities, highlighting the importance of understanding and addressing sarcopenia in relation to spinal health.
๐Ÿ“ฐ Publication: Spine 2022
Read MoreAge-Related Spinal Deformity: a Consequence of Sarcopenia?

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!